Elizabeth Czerepak

Ms. Czerepak has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. She most recently served as EVP and Chief Financial Officer of BeyondSpring Inc., a global, clinical stage oncology company. Prior to that, she served as Chief Financial Officer and Chief Business Officer for Genevant Sciences, a lipid nanoparticle delivery company, and as the chief financial officer for several other biotechs. Ms. Czerepak has 10 years of venture capital investment experience as a former Managing Director at Bear Stearns and JPMorgan, and was Founding General Partner of Bear Stearns Health Innoventures L.P. Ms. Czerepak began her career with 18 years in big pharma in senior leadership positions in finance, strategic planning, business development and commercial launch teams. She led the global partner search for D2E7 (Humira®), which culminated in BASF Pharma’s sale to Abbott for $6.9 billion. She played a key role in Roche’s acquisition of Syntex for $5.4 billion. Over the years, she has also been instrumental in raising hundreds of millions of dollars for biotech companies by leading investments, as well as through her contributions as a CFO and Board member.

Ms. Czerepak holds a B.A. magna cum laude in Spanish and Mathematics Education from Marshall University, an MBA from Rutgers University, and a Corporate Director Certificate from Harvard Business School.